Otorhinolaryngology, Head and Neck Surgery Department, ENTU Clinic, Balıkesir, Turkey.
Vocology Center, İzmir, Turkey.
J Laryngol Otol. 2024 Feb;138(2):224-231. doi: 10.1017/S002221512300110X. Epub 2023 Jun 19.
The main purpose of this study was to retrospectively evaluate the efficiency of DoctorVox voice therapy in psychogenic dysphonia or aphonia patients, and to share the mid- to long-term results of the method.
The study was carried out on patients who underwent DoctorVox voice therapy for psychogenic dysphonia or aphonia between January 2015 and September 2019. The evaluation methods used were: the Voice Handicap Index-10; the grade, roughness, breathiness, asthenia and strain ('GRBAS') scale; and videolaryngostroboscopy recordings.
The mean Voice Handicap Index-10 values of the patients were 30.91 ± 2.97 before treatment, 8.14 ± 3.82 after treatment, and 3.36 ± 1.78 in the final follow-up examination. The grade, roughness, breathiness, asthenia and strain scale scores were: 9 ± 0.67 pre-treatment, 0.78 ± 0.80 post-treatment, and 0.57 ± 0.64 at the final follow up.
DoctorVox voice therapy seems to be an efficient treatment method for psychogenic dysphonia or aphonia; it helps develop phonatory muscle functions, using multidimensional biofeedback mechanisms, and increases the patients' therapy adherence.
本研究旨在回顾性评估 DoctorVox 语音疗法对精神性发声障碍或失音患者的疗效，并分享该方法的中远期结果。
本研究纳入了 2015 年 1 月至 2019 年 9 月期间接受 DoctorVox 语音疗法治疗的精神性发声障碍或失音患者。采用的评估方法包括：嗓音障碍指数-10（Voice Handicap Index-10）；嗓音障碍程度分级、粗糙声、气息声、无力声和紧张度（GRBAS）量表；频闪喉镜检查。
患者治疗前的嗓音障碍指数-10 平均值为 30.91±2.97，治疗后为 8.14±3.82，最终随访时为 3.36±1.78。治疗前的 GRBAS 量表评分分别为：9±0.67，治疗后为 0.78±0.80，最终随访时为 0.57±0.64。
DoctorVox 语音疗法似乎是治疗精神性发声障碍或失音的有效方法；它通过多维生物反馈机制帮助发展发声肌肉功能，提高患者的治疗依从性。
